SENTI-301

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameSENTI-301
Drug Alias NameSENTI-301SENTI-301ASN301A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsGlypican-3 inhibitors +[5] 
TargetsGlypican-3Interleukin-12 receptorInterleukin-15 receptors
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSenti Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelest Therapeutics (Shanghai) Co LtdSenti Biosciences Inc
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A